Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...es embedded with a telescope,promise to make it ea...do,other activities requiring sharper distance vis...scribe the advantages of these innovative glasses,...e May/June issue of,Journal of Biomedical Optics, ..."This new design has several advantages," says the...
(Date:7/24/2008)...ll/ -- American Oriental,Bioengineering, Inc. (NYS...,second quarter 2008 financial results on Monday, ...mpany will hold a conference call at 5:00 pm ET on...ter 2008 results. Listeners may,access the call by...rnational callers, access code: 41757592. A webcas...
(Date:7/24/2008).../- Poniard,Pharmaceuticals,...y focused,on oncology, today announced that it wil...second quarter results and provide a corporate upd...nt plan for picoplatin, the,Company,s lead product...ef,executive officer, Ronald A. Martell, president...
(Date:7/24/2008).../ -- Sagent Pharmaceuticals, Inc.,a privately-hel...d that it,has launched ceftazidime for injection, ...ntibiotic. Sagent will offer ceftazidime in 1,and ...vials. According to,IMS data, 2007 sales of inject...ately $45.7 million., "Sagent is proud to be prov...
Breaking Biology Technology:Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 2Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 3Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2
... , New Advances in Scanner Design for Super..., , , The Affymetrix Gen...r continued evolution of the GeneChip platform a...g continued feature size reduction for higher reso...ay-based products. The Affymetrix GeneChip Scanner...
... Tunable Parameters of the Affymetrix Expressi...oduction , The Statistical Algorithms in ...set data to generate expression values (Signals an...ciated p-values for every transcript represented o...re used to generate transcript Detection and Chang...
...rometry Application Note , Melissa Chen, ...CA , Introduction , Rapid ide...ixtures is one of the key objectives for the use o...ionally, this approach has utilized 3-dimensional ...LCQ Deca XP Plus and the Finnigan ProteomeX. Recen...
...rometry Application Report , Key Words Se... Equine serum Acepromazine , Gargi Chou...SA , Wayne Skinner and Scott Stanley...oduction , Acepromazine is widely used a...r to better facilitate handling of these large mam...
Other Biology Technology:The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 2The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 3The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 4The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 5The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 6The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 7The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 8The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 9The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 10Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 2Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 3Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 4Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 5Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 6Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 7Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 8Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 9Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 10Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 2Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 3Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 4Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 2Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 3Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 4
(Date:7/23/2008)...enewable fuel source could generate enough electri...,s entire consumption needs and lead to a signific...according to US research published today, Thursday...ntal Research Letters . , The journal paper, ,Co...erting Manure to Biogas, has implications for all...
(Date:7/23/2008)...llectively spend about $1 billion annually could p...ic tons of carbon dioxide per year for the next 25...about that much money to put an end to a tenth of ...e top contributors to greenhouse gas emissions, re...rogram could have potential to reduce global carbo...
(Date:7/23/2008)...ernationally renowned scientists from 12 countries...lia and India to address ancient microscopic foss...ng together the world,s best scientists in the fie...iam Schopf, founder and director of the UCLA Insti...or the Study of Evolution and the Origin of Life (...
(Date:7/23/2008)...ards and Technology (NIST) have developed a techni... in protein-based pharmaceuticals. This first syst... scientists can be assured that their instruments ...aggregates, a major concern because of its impact ...ufacturing. , Proteins, a main constituent of ma...
Breaking Biology News(10 mins):Cow power could generate electricity for millions 2Paying to save tropical forests could be a way to reduce global carbon emissions 2Paying to save tropical forests could be a way to reduce global carbon emissions 3Paying to save tropical forests could be a way to reduce global carbon emissions 4UCLA 'world summit' to explore ancient life on Earth, and beyond 2NIST trumps the clumps: Making biologic drugs safer 2Safer easier system for remote explosive detection 4506 1Safer easier system for remote explosive detection 4506 2CamelBak 28R 29 CEO Statement on BPA and Plastic Re Usable Water Bottles 16442 1Haemacure Reports on its annual general and special meeting of shareholders 16438 1Haemacure Reports on its annual general and special meeting of shareholders 16438 2Haemacure Reports on its annual general and special meeting of shareholders 16438 3Haemacure Reports on its annual general and special meeting of shareholders 16438 4Aerobic Exercise Keeps You Young 16434 1Aerobic Exercise Keeps You Young 16434 2
...ure climate shows that the Sahel region, which exp... in the 1990s, could experience wetter monsoons fo...n Africa is projected to intensify further. Oceani...e gases appears to be a factor in these expected 2...Hurrell of the National Center for Atmospheric Res...
...d other causes of Sick Building Syndrome may impro... American Phytopathological Society (APS). , Sick...which building occupants experience health problem... issues typically associated with SBS range from a...problems involving exposure to toxins. , Mold is a...
...in plant science. , Scientists have known since 1...ey,ve known of its dramatic effects on plant growt... scientists know how it works. , In this week,s Na...rk Estelle, Nihal Dharmasiri and Sunethra Dharmasi...influences how and when plant cells grow and divid...
...mols suppress the growth of human cell lines repre...ary, pancreas, brain and blood, and reduce tumors ...addition, Enigmols did not show side effects at ef... at the Georgia Institute of Technology, Emory Uni...re funded by the National Cancer Institute. , "Ma...
Other Biology News:Africa to take it on chin again with climate change 2Africa to take it on chin again with climate change 3What's really making you sick? Plant pathologists offer the science behind Sick Building Syndrome 2At long last, scientists figure out how plants grow 2Researchers find promising cancer-fighting power of synthetic cell-signaling molecule 2Researchers find promising cancer-fighting power of synthetic cell-signaling molecule 3
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST).
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES
LTQ XL Linear Ion Trap from Thermo Scientific
Biology Products: